Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
78 hedge funds and large institutions have $273M invested in Adamas Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 11 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less capital invested
Capital invested by funds: $273M → $273M (-$47.7K)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
4% less funds holding
Funds holding: 81 → 78 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$8.29M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.94M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.5M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$841K |
| 5 |
BWCA
Brenner West Capital Advisors
New York
|
+$807K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.75M |
| 2 |
NC
Nexthera Capital
New York
|
-$1.97M |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
-$1.93M |
| 4 |
BOS
Bingham Osborn & Scarborough
San Francisco,
California
|
-$1.82M |
| 5 |
CPH
C Partners Holding
Zurich,
Switzerland
|
-$973K |
ADMS Hedge Fund Activity: Q4 2016 in Review
78 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2016, worth a combined $273M — down 0.02% from $273M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADMS and 10 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 28 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $8.29M. The largest seller was Millennium Management, cutting an estimated $2.75M.
- 78 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2016, down from 81 in Q3 2016.
- Funds reported $273M of Adamas Pharmaceuticals stock for Q4 2016, down 0.02% quarter-over-quarter.
- 10 funds opened new Adamas Pharmaceuticals positions in Q4 2016 and 11 closed out, a net change of -1 holder.
- The largest Adamas Pharmaceuticals buyer in Q4 2016 was Armistice Capital, an estimated $8.29M added.
- The largest Adamas Pharmaceuticals seller in Q4 2016 was Millennium Management, an estimated $2.75M sold.
Based on aggregated 13F filings for Q4 2016.